Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr. Kremyanskaya on the Next Steps of the MANIFEST Trial in Myelofibrosis

January 3rd 2022

Marina Kremyanskaya, MD, PhD, discusses the next steps of the phase 1/2 MANIFEST trial in myelofibrosis.

Ruxolitinib Combos Are Making Strides in Myelofibrosis and MPNs

January 3rd 2022

Marina Kremyanskaya, MD, PhD, discusses potential new combinations for treating patients with myelofibrosis and other MPNs, with a backbone of ruxolitinib.

Novel Agents Shake Up Myelodysplastic Syndrome Treatment Landscape

December 27th 2021

During a recent OncLive Peer Exchange®, a panel of hematologic cancer experts shared their insights on the most recent FDA-approved agents for MDS, including luspatercept and decitabine/cedazuridine (Inqovi), both of which were approved in 2020.

An Introduction to Myeloproliferative Neoplasms

December 23rd 2021

Jamile Shammo, MD, FACP, FASCP, provides an overview of the different types of myeloproliferative neoplasms.

Dr. Kremyanskaya on the Design of the MANIFEST Trial in Myelofibrosis

December 21st 2021

Marina Kremyanskaya, MD, PhD, discusses the design of the phase 1/2 MANIFEST trial in myelofibrosis.

Full-Dose Pacritinib Bests Ruxolitinib for Patients With Cytopenic Myelofibrosis

December 14th 2021

Most patients with myelofibrosis with moderate to severe thrombocytopenia treated with pacritinib were able to maintain full dose intensity over time and had numerically higher rates of symptom response vs those who received ruxolitinib.

Serum Ferritin Predicts Treatment Response in Myelofibrosis for Those Assigned to Momelotinib

December 14th 2021

Serum ferritin at baseline was a predictor for week 24 transfusion independence response in patients with myelofibrosis receiving momelotinib according to findings from an analysis of data from the phase 3 SIMPLIFY trials.

Pacritinib Shows Manageable Safety Profile in Cytopenic Myelofibrosis, Severe Thrombocytopenia

December 14th 2021

Treatment with pacritinib, when administered at 200 mg twice daily, had a comparable safety profile to best available therapy in patients with cytopenic myelofibrosis, including those with severe thrombocytopenia.

IPSS, JAK2 Status May Identify Risk for Thrombosis in Primary Myelofibrosis

December 12th 2021

The use of the International Prognostic Scoring System score and JAK2 mutation status may identify patients at risk for major arterial and venous thrombosis in primary myelofibrosis, and suggests appropriate anti-thrombotic prophylaxis.

Hypoxic Blood May Improve Outcomes for Patients With MDS Requiring Transfusions

December 11th 2021

Paul M. Ness, MD, discusses the goal of the Hemanext ONE® blood storage system and the potential benefit of this approach for those with myelodysplastic syndrome and other conditions that require transfusions.

Dr. Harrison on the Current State of Treatment in Myelofibrosis

December 1st 2021

Claire Harrison, MD, FRCP, FRCPath, discusses the current state of treatment in myelofibrosis.

FDA Extends Review Period for Pacritinib in Myelofibrosis With Severe Thrombocytopenia

November 30th 2021

The FDA has extended the review period for the new drug application for pacritinib as a treatment for adult patients with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis and severe thrombocytopenia with a baseline platelet count of 50 x 109/L.

Incorporating Mutational Panel Testing Remains Crucial in MDS

November 24th 2021

David Sallman, MD, discusses incorporating mutational testing of patients with myelodysplastic syndrome into clinical practice, and strategies that can be utilized to treat this population.

Dr. Mesa on Navigating the Expanding Paradigm of JAK Inhibitors in MPNs

November 19th 2021

Ruben A. Mesa, MD, discusses strategies for navigating the expanding paradigm of JAK inhibitors in myeloproliferative neoplasms.

FDA Approves Ropeginterferon Alfa-2b-njft for Polycythemia Vera

November 13th 2021

The FDA has approved ropeginterferon alfa-2b-njft for use as a treatment in patients with polycythemia vera.

Treatment Options Continue to Increase in Low-Risk MDS

November 3rd 2021

Azanucleosides, such as azacitidine, remain the backbone of disease-modifying therapy for patients with myelodysplastic syndromes, however, new adjuncts are leading to longer remissions and disease-free survival in patients with low-risk disease.

Dr. Kuykendall on the Potential for Momelotinib in Myelofibrosis

November 2nd 2021

Andrew T. Kuykendall, MD, discusses the potential for momelotinib in the treatment of patients with myelofibrosis.

Ruxolitinib Found Not to Increase the Risk for Secondary Malignancies in Polycythemia Vera

October 28th 2021

Treatment with ruxolitinib was not found to carry an increased risk of secondary malignancies in patients with polycythemia vera.

Dr. Verstovsek on the Benefit of JAK Inhibitor Combos in Myelofibrosis

October 13th 2021

Srdan Verstovsek, MD, PhD, discusses the benefit of drug combinations to improve anemia in patients with myelofibrosis.

Dr. Rampal on the Importance of Risk Stratification in Myelofibrosis

October 12th 2021

Raajit K. Rampal, MD, PhD, discusses the importance of risk stratification in myelofibrosis.